# Sulfonylureas

| Override(s) | Approval Duration |
|---|---|
| Prior Authorization<br>Quantity Limit | 1 year |

| Medications | Quantity Limit |
|---|---|
| Sulfonylureas | May be subject to quantity limit |

## APPROVAL CRITERIA

Requests for sulfonylureas may be approved if the following criteria are met:

I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to metformin(AACE/ACE 2020);
**OR**
II. Individual has a contraindication to metformin therapy [including but not limited to, renal insufficiency (eGFR is less than 45 mL/minute/1.73 $m^2$)];

**AND**
III. Individual will not use sulfonylureas in combination with meglitinide agents [Starlix (nateglinide), repaglinide/metformin, or repaglinide].

**Note:**

Glipizide/metformin and glyburide/metformin have a black box warning for lactic acidosis as they contain metformin. Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias. Risk factors include renal impairment, concomitant use of certain agents, age > 65 years, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake and hepatic impairment. If lactic acidosis is suspected, discontinue the metformin-containing agent and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.

**Key References**:


1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: January 17, 2021.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Garber AJ, Handelsman Y, Grunberger G, et. al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. *Endocrine Practice*. 2020;26:107-139.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2021; Updated periodically.
5. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed: January 15, 2021.





Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.